| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $6.3M | +8.0% | +5.3% |
| SG&A Expense | $7.3M | -3.4% | +73.1% |
| Operating Income | -$13.6M | -1.5% | -33.3% |
| Net Income | -$11.9M | -0.8% | -27.6% |
| EPS (Basic) | -$0.24 | +7.7% | +0.0% |
| EPS (Diluted) | -$0.24 | +7.7% | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $184.8M | -2.1% | +78.4% |
| Accounts Receivable | $3K | -97.7% | +0.0% |
| Current Assets | $186.0M | -1.9% | +78.8% |
| Total Assets | $187.0M | -1.9% | +77.7% |
| Current Liabilities | $3.3M | +16.9% | -53.4% |
| Total Liabilities | $3.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.6M | — | — |
| Capital Expenditures | $26K | — | — |
| Investing Cash Flow | -$26K | — | — |
| Financing Cash Flow | $98.7M | — | — |
| Free Cash Flow | -$11.6M | — | — |
| -52.0% |
| Stockholders' Equity | $183.3M | -2.2% | +87.9% |